🔎 Trials Near Me

Utama › Leukemia Biphenotipik Akut › New York › New York City

Kajian klinikal Leukemia Biphenotipik Akut di New York City, NY

10 kajian untuk Leukemia Biphenotipik Akut sedang mencari peserta di lokasi dalam dan sekitar New York City (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Mengambil pesertaFasa 1
  • Memorial Sloan Kettering Cancer Center, New York
Umur 12 hingga 78 · Semua jantina · Dikemas kini 29 Sep 2026 · NCT03802695

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Mengambil pesertaFasa 2
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
  • Memorial Sloan Kettering Cancer Center, New York
  • NYP/Weill Cornell Medical Center, New York
365 Days · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06317662

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Mengambil pesertaFasa 1/2
  • Montefiore Medical Center, New York
30 Days · Semua jantina · Dikemas kini 16 Sep 2026 · NCT04065399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Mengambil pesertaFasa 3
  • Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
  • Mount Sinai Hospital, New York
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
  • dan 2 lagi
365 Days – 25 Years · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Mengambil pesertaFasa 1/2
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
  • Memorial Sloan Kettering Cancer Center, New York
Sehingga umur 22 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04726241

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Mengambil pesertaFasa 1
  • Memorial Sloan- Kettering Cancer Center, New York
Umur 1 hingga 30 · Semua jantina · Dikemas kini 3 Ogo 2026 · NCT06177067

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Mengambil pesertaFasa 2
  • Weill Cornell Medicine - New York Presbyterian Hospital, New York
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Jul 2026 · NCT07216443

A Study of Revumenib and Mezigdomide in People With Leukemia

Mengambil pesertaFasa 1/2
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Umur 12 ke atas · Semua jantina · Dikemas kini 22 Jun 2026 · NCT07356154

Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL

Mengambil pesertaFasa 1
  • Memorial Sloan Kettering Cancer Center, New York
Umur 12 ke atas · Semua jantina · Dikemas kini 8 Jan 2026 · NCT04872478

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Mengambil pesertaFasa 1
  • Children's Hospital New York-Presbyterian, New York
  • Memorial Sloan Kettering Cancer Center, New York
Umur 1 hingga 21 · Semua jantina · Dikemas kini 6 Dis 2024 · NCT05476770

Kajian Leukemia Biphenotipik Akut di bandar lain

Kajian lain di New York City

Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.